In experimental MS models, rapamycin with mTOR inhibition can prevent the clinical course of both relapsing-remitting and chronic experimental autoimmune encephalomyelitis, suggesting important clinical applications for the treatment of MS [201]. This evidence concerns the gene MTOR and myeloid sarcoma.